Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference
BRISBANE, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that members of senior management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 9:00 a.m. ET.
加利福尼亞布里斯班，2024年11月25日（環球新聞社） - Tempest Therapeutics, Inc.（納斯達克：TPST），一家臨床階段的生物技術公司，正在開發首個類別靶向和免疫介導的治療藥物來對抗癌症，今天宣佈，高級管理團隊成員將於2024年12月3日星期二上午9:00參加派傑投資第36屆年度醫療保健大會上的爐邊對談。
To access the live or archived recording of the discussion, please visit the investor section of the Tempest website at .
要訪問討論的直播或存檔記錄，請訪問Tempest網站的投資者部分 .
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company's novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company's website at .
關於 Tempest Therapeutics
Tempest Therapeutics是一家臨床階段的生物技術公司，推進着包含腫瘤靶向和/或免疫介導機制的多種小分子藥物候選品的多元組合，有望治療各種腫瘤。該公司的新穎方案從早期研究到全球隨機一線癌症患者的後期調查。Tempest位於加利福尼亞州的布里斯班。有關Tempest的更多信息，請訪問該公司的網站。.
Investor Contacts:
投資者聯繫方式：
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Sylvia Wheeler
Wheelhouse 生命科學顧問公司
swheeler@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse 生命科學顧問公司
areynolds@wheelhouselsa.com
_______________________________
i If approved by the FDA
_______________________________
如果被FDA批准
譯文內容由第三人軟體翻譯。
